# Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference Canonical URL: https://biopharmsignal.com/news/FBIO/journey-medical-corporation-to-participate-in-a-g-p-s-annual-virtual-healthcare-conference Ticker: FBIO Company: Fortress Biotech Source: Fortress Biotech Published: 2026-06-25 13:46 EST Original Source URL: https://www.fortressbiotech.com ## Summary

SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment ## Article Body SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 5:00pm ET. To register for the conference, visit the A.G.P. Registration Link. About Journey Medical Corporation Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com. Company Contact: Jaclyn Jaffe (781) 652-4500 ir@jmcderm.com Media Relations Contact: Tony Plohoros 6 Degrees (908) 591-2839 tplohoros@6degreespr.com Source: Journey Medical Corporation ## Recent Company News - 2026-06-25 13:46 EST — [Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference](https://biopharmsignal.com/news/FBIO/journey-medical-corporation-to-participate-in-a-g-p-s-annual-virtual-healthcare-conference) — Source: Fortress Biotech - 2026-06-25 13:46 EST — [Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™](https://biopharmsignal.com/news/FBIO/journey-medical-corporation-secures-contract-with-third-major-gpo-for-emrositm) — Source: Fortress Biotech - 2026-06-25 13:46 EST — [Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference](https://biopharmsignal.com/news/FBIO/fortress-biotech-to-participate-in-a-g-p-s-annual-virtual-healthcare-conference) — Source: Fortress Biotech - 2026-06-25 13:46 EST — [Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/FBIO/fortress-biotech-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights) — Source: Fortress Biotech - 2026-06-25 13:46 EST — [Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/FBIO/journey-medical-corporation-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights) — Source: Fortress Biotech ## Related News - 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47) - 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640) - 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0) - 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f) - 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)